Drug Trial Radar · NCT06531811
A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.
Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 6, 2024
Primary completion
Oct 3, 2024
Study completion Oct 3, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the potential difference between pharmacokinetics (PK), safety, tolerability and device performance between the AZD8630 test formulation and the AZD8630 reference formulation.
Conditions
- Healthy Participants
Interventions
AZD8630 (test formulation) via test inhalerDrug
Participants will receive AZD8630 via test inhaler.
AZD8630 (reference formulation) via Monodose inhalerDrug
Participants will receive AZD8630 via Monodose inhaler.
Test inhalerDevice
Participants will receive AZD8630 via test inhaler.
Monodose inhalerDevice
Participants will receive AZD8630 via Monodose inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time zero to the last quantifiable concentration test/MonodoseTime frame: From Baseline Day 1 to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.